Integrating BCMA-Based Combination Regimens in Early R/R Multiple Myeloma

It is challenging to manage patients with multiple myeloma who are refractory to previous treatments, particularly those who are refractory to CD38 antibodies. In this MEDtalk from EHA23, Dr. Popat shares his insights on second-line treatment strategies and sheds light on the integration of BCMA-based combination regimens, including antibody-drug conjugates, bispecific T-cell engagers, and CAR T-cell therapy.